Actively Recruiting
Open-Label Feasibility Study of Subcutaneous Elranatamab Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV After Frontline Therapy
Led by University of Illinois Chicago · Updated on 2026-10-26
17
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on patients with plasmablastic lymphoma PBL, both with and without HIV infection, who have completed frontline chemotherapy and achieved either a complete or partial response. The study aims to evaluate the feasibility, safety, and effectiveness of using Elranatamab Elra as a consolidation therapy following initial treatment. It is a phase 1, single-arm, open-label study sponsored by the University of Illinois Chicago. Participants receive Elranatamab administered under a step-up dosing schedule subcutaneously across six 28-day cycles. The first cycle involves doses on days 1, 4, 8, 15, and 22, transitioning in cycles 2 and 3 to dosing every two weeks, followed by an interim PETCT scan. Cycles 4 through 6 involve dosing every four weeks. This schedule is designed to assess the treatments tolerability and impact on disease control. During and after treatment, participants undergo regular disease assessments with PETCT scans at the end of cycle 3, at the conclusion of treatment, and every six months up to two years to monitor for recurrence and survival. Routine clinical follow-up visits occur every three months according to standard care. Researchers will evaluate response rates, safety, progression-free survival, quality of life, and effects on immune cell counts and viral load over the course of the study, which may last up to four years from enrollment.
CONDITIONS
Brief Title
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Research Team
P
Paul Rubinstein, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here